Terns Pharmaceuticals Secures Exclusive Worldwide Rights to TERN-701 Patents from Hansoh
Summary
Terns Pharmaceuticals amended its agreement with Hansoh, gaining exclusive worldwide rights to Hansoh-invented patents related to its therapeutic product TERN-701 for a $1.0 million upfront fee.
Key Events
-
Exclusive Worldwide License Secured
Terns Pharmaceuticals obtained an exclusive, royalty-bearing, sublicensable, perpetual, and worldwide license (excluding mainland China, Taiwan, Hong Kong, and Macau) to patents invented by Hansoh related to TERN-701 products.
-
Replaces Prior Non-Exclusive Rights
This new exclusive license supersedes a previous non-exclusive, non-sublicensable, royalty-free license held by a Terns subsidiary for the same Hansoh-invented patents.
-
Financial Terms
Terns will pay Hansoh a one-time upfront license fee of $1.0 million and tiered royalties ranging from 0.75% to 1.25% on annual net sales of TERN-701 products in its licensed territory.
Analysis
Terns Pharmaceuticals has significantly strengthened its intellectual property position for TERN-701 by securing an exclusive, worldwide license (excluding the Hansoh Territory) to patents invented by Hansoh. This amendment replaces a previous non-exclusive license, granting Terns full control over the development and commercialization of TERN-701 products globally. The upfront payment of $1.0 million is a modest cost for such a strategic gain, enhancing the long-term value and market potential of TERN-701.
At the time of this filing, TERN was trading at $36.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $1.87 to $48.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.